Base de dados : MEDLINE
Pesquisa : B01.650.940.800.575.912.250.093.750 [Categoria DeCS]
Referências encontradas : 263 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 27 ir para página                         

  1 / 263 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28436684
[Au] Autor:Ooi SL; Pak SC
[Ad] Endereço:1 Centre of Complementary and Alternative Medicine , Singapore, Singapore .
[Ti] Título:Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine.
[So] Source:J Altern Complement Med;23(8):599-606, 2017 Aug.
[Is] ISSN:1557-7708
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Benign prostatic hyperplasia (BPH) commonly affects men above 40 years old. The progression of BPH is often accompanied with lower urinary tract symptoms (LUTS) that can significantly affect the quality of life of the patients. Serenoa repens (saw palmetto) is a popular herbal remedy indicated for LUTS/BPH. We reviewed the current research on the efficacy of S. repens on LUTS/BPH as a monotherapy as well as combination therapies. DESIGN: Non-systematic searches were performed in PubMed for human studies and systematic reviews on the topic. RESULTS: The latest evidence, based largely on the Cochrane review, suggests that S. repens is not superior to placebo in treating LUTS/BPH as a monotherapy, even at double and triple doses. Initial clinical trials on treatment of LUTS/BPH using S. repens with lycopene and selenium, as well as S. repens with Urtica Dioica, have shown positive results. S. repens is safe in its application. However, there is a high level of heterogeneity in the quality of S. repens products. We suggest that strong placebo effect, potentially influenced by positive patients' expectation on S. repens, shapes both the clinical practice outcomes and the findings of clinical trials. Hitherto, the totality of evidence continues to suggest that S. repens is a prudent therapeutic option as part of the naturopathic treatment for LUTS/BPH. CONCLUSIONS: The totality of evidence includes favorable patients' response from clinical experience, impact of placebo effect, early positive studies, subjective nature of symptom reporting, pharmacological properties of S. repens, and potential synergistic effects when combined with other therapies.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Extratos Vegetais/uso terapêutico
Hiperplasia Prostática/tratamento farmacológico
Serenoa/química
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Seres Humanos
Masculino
Meia-Idade
Naturopatia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Plant Extracts); J7WWH9M8QS (saw palmetto extract)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170425
[St] Status:MEDLINE
[do] DOI:10.1089/acm.2016.0302


  2 / 263 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28327526
[Au] Autor:Morgia G; Micali A; Rinaldi M; Irrera N; Marini H; Puzzolo D; Pisani A; Privitera S; Russo GI; Cimino S; Ieni A; Trichilo V; Altavilla D; Squadrito F; Minutoli L
[Ad] Endereço:Department of Urology, Polyclinic Hospital, University of Catania, 95124 Catania, Italy. gmorgia@policlinico.unict.it.
[Ti] Título:Survivin and NAIP in Human Benign Prostatic Hyperplasia: Protective Role of the Association of Serenoa repens, Lycopene and Selenium from the Randomized Clinical Study.
[So] Source:Int J Mol Sci;18(3), 2017 Mar 22.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Benign prostatic hyperplasia (BPH) treatment includes the apoptosis machinery modulation through the direct inhibition of caspase cascade. We previously demonstrated that (Ser) with lycopene (Ly) and selenium (Se) reawakened apoptosis by reducing survivin and neuronal apoptosis inhibitory protein (NAIP) levels in rats. The aim of this study was to evaluate the effectiveness of Ser-Se-Ly association on survivin and NAIP expression in BPH patients. Ninety patients with lower urinary tract symptoms (LUTS) due to clinical BPH were included in this randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to receive placebo (Group BPH + placebo, = 45) or Ser-Se-Ly association (Group BPH + Ser-Se-Ly; = 45) for 3 months. At time 0, all patients underwent prostatic biopsies. After 3 months of treatment, they underwent prostatic re-biopsy and specimens were collected for molecular, morphological, and immunohistochemical analysis. After 3 months, survivin and NAIP were significantly decreased, while caspase-3 was significantly increased in BPH patients treated with Ser-Se-Ly when compared with the other group. In BPH patients treated with Ser-Se-Ly for 3 months, the glandular epithelium was formed by a single layer of cuboidal cells. PSA showed high immunoexpression in all BPH patients and a focal positivity in Ser-Se-Ly treated patients after 3 months. Evident prostate specific membrane antigen (PSMA) immunoexpression was shown in all BPH patients, while no positivity was present after Ser-Se-Ly administration. Ser-Se-Ly proved to be effective in promoting apoptosis in BPH patients.
[Mh] Termos MeSH primário: Proteínas Inibidoras de Apoptose/metabolismo
Proteína Inibidora de Apoptose Neuronal/metabolismo
Hiperplasia Prostática/metabolismo
Hiperplasia Prostática/patologia
[Mh] Termos MeSH secundário: Idoso
Antígenos de Superfície/genética
Antígenos de Superfície/metabolismo
Apoptose/efeitos dos fármacos
Biomarcadores
Carotenoides/farmacologia
Regulação da Expressão Gênica/efeitos dos fármacos
Glutamato Carboxipeptidase II/genética
Glutamato Carboxipeptidase II/metabolismo
Seres Humanos
Imuno-Histoquímica
Proteínas Inibidoras de Apoptose/genética
Masculino
Meia-Idade
Proteína Inibidora de Apoptose Neuronal/genética
Extratos Vegetais/farmacologia
Hiperplasia Prostática/etiologia
Hiperplasia Prostática/prevenção & controle
Selênio/farmacologia
Compostos de Selênio/farmacologia
Serenoa/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Surface); 0 (BIRC5 protein, human); 0 (Biomarkers); 0 (Inhibitor of Apoptosis Proteins); 0 (Neuronal Apoptosis-Inhibitory Protein); 0 (Plant Extracts); 0 (Selenium Compounds); 36-88-4 (Carotenoids); EC 3.4.17.21 (Glutamate Carboxypeptidase II); EC 3.4.17.21 (glutamate carboxypeptidase II, human); H6241UJ22B (Selenium); SB0N2N0WV6 (lycopene)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170420
[Lr] Data última revisão:
170420
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE


  3 / 263 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27583656
[Au] Autor:Quarto G; Cola A; Perdonà S
[Ad] Endereço:Unit of Urology, G. Pascale Foundation and Institute for Cancer Research and Care, Naples, Italy - giuseppe.quarto@gmail.com.
[Ti] Título:Efficacy of a formulation containing Serenoa repens, Crocus sativus and Pinus massoniana extracts in men with concomitant LUTS and erectile dysfunction.
[So] Source:Minerva Urol Nefrol;69(3):300-306, 2017 Jun.
[Is] ISSN:1827-1758
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) has received increased attention recently. This study aims to evaluate the efficacy of IDIProst® Gold, a product containing Serenoa repens, Crocus sativus and Pinus massoniana bark extract (PMBE), in improving sexual function, urinary symptoms and quality of life in patients with concomitant LUTS and ED. METHODS: A total 140 men (mean age 48 years) were enrolled and treated in this study. All patients were administered IDIProst® Gold (Crocus sativus, PMBE, Serenoa repens) once daily for three months. At visit (T0) and after ninety days of treatment (T90), the patients were evaluated and asked to complete two self-administered questionnaires: International Prostate Symptoms Score (IPSS), International Index of Erectile Function (IIEF-5). The main outcomes were the improved IIEF-5 and IPSS scores in the 40-60 age group. The secondary outcome was the improved quality of life score among treated patients. RESULTS: The baseline mean scores at T0 were 17.29 and 15.12 for the IPSS and IIEF-5 respectively. After three months of treatment (T90), the questionnaire results were as follows: 10.21 and 20.53 for IPSS and IIEF-5 respectively. Statistically significant differences (P<0.001) were reported between the two visits in terms of IPSS and IIEF-5 for all the groups treated, but particularly the 40-60 age group. There was also a statistically significant improvement (P<0.001) in quality of life between T0 and T90 (3.82 vs. 1.45). Compliance with the study protocol was 100%. 140 patients were enrolled out of a population of 164. No adverse events were reported. CONCLUSIONS: Treatment once daily with IDIProst® Gold (Serenoa repens, Crocus sativus and PMBE) for three months significantly improved sexual function, urinary symptoms and quality of life in patients with concomitant LUTS and ED, especially in the 40-60 age group.
[Mh] Termos MeSH primário: Crocus/química
Disfunção Erétil/tratamento farmacológico
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Pinus/química
Extratos Vegetais/uso terapêutico
Serenoa/química
[Mh] Termos MeSH secundário: Adulto
Seres Humanos
Masculino
Meia-Idade
Qualidade de Vida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Plant Extracts)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171003
[Lr] Data última revisão:
171003
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160902
[St] Status:MEDLINE
[do] DOI:10.23736/S0393-2249.16.02661-8


  4 / 263 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27711089
[Au] Autor:Cai T; Tiscione D; Gallelli L; Verze P; Palmieri A; Mirone V; Bartoletti R; Malossini G
[Ad] Endereço:Department of Urology, Santa Chiara Regional Hospital, Trento. ktommy@libero.it.
[Ti] Título:Serenoa repens associated with selenium and lycopene extract and bromelain and methylsulfonylmethane extract are able to improve the efficacy of levofloxacin in chronic bacterial prostatitis patients.
[So] Source:Arch Ital Urol Androl;88(3):177-182, 2016 Oct 05.
[Is] ISSN:1124-3562
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To date, the management of patients with chronic bacterial prostatitis (CBP) is not satisfactory, especially in terms of symptoms relief. Here, we evaluated the efficacy and the safety of a combination of serenoa repens, selenium and lycopene extract + bromelain and methylsulfonylmethane extract associated with levofloxacin in patients with CBP. MATERIALS AND METHODS: All patients with clinical and instrumental diagnosis of CBP, admitted to a single Urological Institution from March to June 2015 were enrolled in this phase III study. All enrolled patients were randomized into two groups: Group A received levofloxacin 500 mg o.d. for 14 days associated with lycopene and methylsulfonylmethane; Group B received levofloxacin (500 mg o.d. for 14 days) only. Clinical and microbiological analyses were carried out at the time of admission (T0) and during the followups at 1 month (T1) and 6 months (T2) from the end of the treatment. NIH Chronic Prostatitis Symptom Index (CPSI), International Prostatic Symptom Score (IPSS) and Quality of Well-Being (QoL) questionnaires were used. The main outcome measures were the rate of microbiological cure and the improvement in questionnaire results from baseline at the end of the follow-ups period. RESULTS: Forty patients were enrolled in Group A and 39 in Group B. During the follow-up (T1), we recorded a significant changes in terms of NIH-CPSI and IPSS in Group A (mean difference: 17.6 ± 2.65; 12.2 ± 2.33; p < 0.01; p < 0.05, respectively) and versus Group B at the intergroup analysis (mean difference: -9 ± 1.82; -8.33 ± 1.71; p < 0.05; p < 0.05, respectively). No differences were reported in terms of microbiological findings between the two groups. At the second follow-up visit (T2), questionnaire results demonstrated statistically significant differences between groups (p < 0.001). One patient in Group A (2.5%) and 7 patients (17.9%) in Group B showed a symptomatic and microbiological recurrence (p = 0.02). CONCLUSIONS: The combination of serenoa repens, selenium, lycopene + bromelain and methylsulfonylmethane extracts improved the clinical efficacy of levofloxacin in patients affected by CBP without the development of side effects.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Levofloxacino/uso terapêutico
Extratos Vegetais/uso terapêutico
Prostatite/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Antibacterianos/administração & dosagem
Antibacterianos/efeitos adversos
Bromelaínas/administração & dosagem
Bromelaínas/efeitos adversos
Bromelaínas/uso terapêutico
Carotenoides/administração & dosagem
Carotenoides/efeitos adversos
Carotenoides/uso terapêutico
Doença Crônica
Dimetil Sulfóxido/administração & dosagem
Dimetil Sulfóxido/efeitos adversos
Dimetil Sulfóxido/uso terapêutico
Quimioterapia Combinada
Seguimentos
Seres Humanos
Levofloxacino/administração & dosagem
Levofloxacino/efeitos adversos
Masculino
Extratos Vegetais/administração & dosagem
Extratos Vegetais/efeitos adversos
Estudos Prospectivos
Prostatite/microbiologia
Selênio/administração & dosagem
Selênio/efeitos adversos
Selênio/uso terapêutico
Serenoa/química
Sulfonas/administração & dosagem
Sulfonas/efeitos adversos
Sulfonas/uso terapêutico
Inquéritos e Questionários
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Plant Extracts); 0 (Sulfones); 36-88-4 (Carotenoids); 6GNT3Y5LMF (Levofloxacin); 9001-00-7 (Bromelains); 9H4PO4Z4FT (dimethyl sulfone); H6241UJ22B (Selenium); SB0N2N0WV6 (lycopene); YOW8V9698H (Dimethyl Sulfoxide)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170111
[Lr] Data última revisão:
170111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161007
[St] Status:MEDLINE
[do] DOI:10.4081/aiua.2016.3.177


  5 / 263 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27558894
[Au] Autor:Arena S
[Ad] Endereço:a Department of Human Pathology in Adult and Developmental Age 'Gaetano Barresi' , University of Messina , Messina , Italy.
[Ti] Título:Letter to the editorResponse to: Russo A, Capogrosso P, La Croce G, et al. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. Expert Opin Drug Saf. 2016 Jun;1:1-10.
[So] Source:Expert Opin Drug Saf;15(10):1449, 2016 10.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Hiperplasia Prostática/tratamento farmacológico
Serenoa
[Mh] Termos MeSH secundário: Seres Humanos
Sintomas do Trato Urinário Inferior/tratamento farmacológico
Fitoterapia
Extratos Vegetais/uso terapêutico
Selênio/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Plant Extracts); H6241UJ22B (Selenium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170421
[Lr] Data última revisão:
170421
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160826
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2016.1228556


  6 / 263 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27232207
[Au] Autor:Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
[Ad] Endereço:a Department of Urology , Università Vita-Salute San Raffaele , Milan , Italy.
[Ti] Título:Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
[So] Source:Expert Opin Drug Saf;15(12):1661-1670, 2016 Dec.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Benign prostatic hyperplasia (BPH) is a disease affecting most of the elderly male. α1-blockers and 5-alpha reductase inhibitors are currently used to target lower urinary tract symptoms (LUTS). Moreover phytotherapeutic agents, including Serenoa Repens (SeR), have shown to have a role in ameliorating BPH/LUTS alone or in combination of other elements like Selenium (Se) and Lycopene (Ly). Areas covered: A literature review was performed using data from articles assessing the role of of SeR+Se+Ly in the management of LUTS secondary to BPH. Diverging evidence on SeR's efficacy is available. On one hand several studies have shown SeR efficacy in treating BPH/LUTS. SeR is effective in reducing prostate size, urinary frequency, dysuria, nocturia and in improving maximum urine flow-rate. On the other hand two long-term trials reported that SeR did not improve prostate size or urinary flow. SeR+Se+Ly in combination with tamsulosin is more effective than single therapies in improving IPSS and increasing maximal urinary flow-rate in patients affected by LUTS/BPH. Expert opinion: Despite great amount of preclinical and clinical studies, the use of SeR in BPH/LUTS is not sustained by clear evidence for a therapeutic efficacy but current data hint higher efficacy of of SeR+Se+Ly compared to SeR alone.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Hiperplasia Prostática/tratamento farmacológico
Serenoa/química
[Mh] Termos MeSH secundário: Idoso
Animais
Carotenoides/administração & dosagem
Carotenoides/uso terapêutico
Quimioterapia Combinada
Seres Humanos
Sintomas do Trato Urinário Inferior/etiologia
Masculino
Fitoterapia/métodos
Extratos Vegetais/administração & dosagem
Extratos Vegetais/uso terapêutico
Hiperplasia Prostática/complicações
Selênio/administração & dosagem
Selênio/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Plant Extracts); 36-88-4 (Carotenoids); H6241UJ22B (Selenium); SB0N2N0WV6 (lycopene)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170420
[Lr] Data última revisão:
170420
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160528
[St] Status:MEDLINE


  7 / 263 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26010505
[Au] Autor:Wessagowit V; Tangjaturonrusamee C; Kootiratrakarn T; Bunnag T; Pimonrat T; Muangdang N; Pichai P
[Ad] Endereço:Molecular Genetics Unit, Institute of Dermatology, Bangkok, Thailand.
[Ti] Título:Treatment of male androgenetic alopecia with topical products containing Serenoa repens extract.
[So] Source:Australas J Dermatol;57(3):e76-82, 2016 Aug.
[Is] ISSN:1440-0960
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/OBJECTIVES: Male androgenetic alopecia (AGA) is a common hair problem. Serenoa repens extract has been shown to inhibit both types of 5-α reductase and, when taken orally, has been shown to increase hair growth in AGA patients. The aim of this study was to assess the efficacy of topical products containing S. repens extract for the treatment of male AGA. METHODS: This was a pilot, prospective, open, within-subject comparison limited to 24 weeks using no placebo controls. In all, 50 male volunteers aged between 20 and 50 years received topical S. repens products for 24 weeks. The primary end-point was a hair count in an area of 2.54 cm(2) at week 24. Secondary end-points included hair restoration, investigators' photographic assessment, patients' evaluation and discovering adverse events. RESULTS: The average hair count and terminal hair count increased at weeks 12 and 24 compared to baseline. Some of these positive results levelled off at week 24, presumably because the concentrated topical product containing S. repens extract was stopped after 4 weeks. The patients were satisfied with the products and the side-effects were limited. CONCLUSIONS: The topical application of S. repens extract could be an alternative treatment in male pattern baldness in male patients who do not want or cannot tolerate the side-effects of standard medications, but the use of a concentrated S. repens product beyond 4 weeks may be necessary for sustained efficacy.
[Mh] Termos MeSH primário: Alopecia/tratamento farmacológico
Cabelo/crescimento & desenvolvimento
Fitoterapia/métodos
Extratos Vegetais/administração & dosagem
Serenoa
[Mh] Termos MeSH secundário: Administração Tópica
Adulto
Alopecia/diagnóstico
Análise de Variância
Cabelo/efeitos dos fármacos
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Prognóstico
Estudos Prospectivos
Medição de Risco
Índice de Gravidade de Doença
Tailândia
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Plant Extracts)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170424
[Lr] Data última revisão:
170424
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150527
[St] Status:MEDLINE
[do] DOI:10.1111/ajd.12352


  8 / 263 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26306400
[Au] Autor:Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
[Ad] Endereço:Institut de Recherche Pierre Fabre, Toulouse, France.
[Ti] Título:Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
[So] Source:Prostate;75(16):1857-67, 2015 Dec.
[Is] ISSN:1097-0045
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Chronic prostatic inflammation (CPI) could be a cause of symptomatic or complicated benign prostatic hyperplasia (BPH). In previous in vitro and in vivo studies, Hexanic Extract of Serenoa repens (HESr) namely Permixon(®) has demonstrated potent anti-inflammatory properties. With the aim to provide new insight onto HESr anti-inflammatory properties in human we explore its effect on CPI biomarkers in men with lower urinary tract symptoms (LUTS) related to BPH using a non-invasive method and investigate links between biomarkers and clinical symptoms. METHODS: An international, randomized, double-blind, parallel-group, tamsulosin-controlled study was carried out in 206 men with BPH-related LUTS. Patients received oral daily HESr 320mg or tamsulosin 0.4 mg during 3 months. The first urine stream after digital rectal examination (DRE) was collected at Day 1 and Day 90 and mRNA was extracted from prostatic epithelial cells desquaming in the lumen of the glands and seminal plasma fluid after DRE. mRNA quantification of the 29 most significant published inflammation markers in BPH and protein detection in urine was performed. RESULTS: At D90, a decrease in mean gene expression was observed for 65.4% of the markers detected in the HESr group versus 46.2% in the tamsulosin group. In the 15 most frequently expressed genes, this difference was higher (80% vs. 33% respectively). Three proteins (MCP-1/CCL2, IP-10/CXCL10, and MIF) were detected. At D90, a decrease in the number of patients who expressed MCP-1/CCL2 and IP-10/CXCL10 was observed only in the HESr group. Moreover, MIF expression was significantly reduced by HESr compared with tamsulosin (P = 0.007). Finally, in contrast to tamsulosin, the subgroup of patients treated by HESr and who over expressed MIF at baseline, had a higher response to the International Prostate Symptom Score (I-PSS) than those who did not over express this protein (mean I-PSS change: -6.4 vs. -4.5 respectively). As the study is exploratory, results should be confirmed in a powered clinical study. CONCLUSIONS: These results showed for the first time at clinical level the anti-inflammatory properties of HESr, already indicated in BPH-related LUTS. Thus, HESr could be of interest to prevent unfavourable evolution in patients with CPI.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Extratos Vegetais/uso terapêutico
Hiperplasia Prostática/complicações
Serenoa
[Mh] Termos MeSH secundário: Idoso
Antagonistas de Androgênios/uso terapêutico
Biomarcadores/urina
Método Duplo-Cego
Seres Humanos
Inflamação/tratamento farmacológico
Inflamação/etiologia
Inflamação/urina
Sintomas do Trato Urinário Inferior/etiologia
Sintomas do Trato Urinário Inferior/urina
Masculino
Meia-Idade
Hiperplasia Prostática/urina
Sulfonamidas/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Biomarkers); 0 (Plant Extracts); 0 (Sulfonamides); G3P28OML5I (tamsulosin); J7WWH9M8QS (saw palmetto extract)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150827
[St] Status:MEDLINE
[do] DOI:10.1002/pros.23059


  9 / 263 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26104840
[Au] Autor:Colado-Velázquez J; Mailloux-Salinas P; Medina-Contreras J; Cruz-Robles D; Bravo G
[Ad] Endereço:Departamento Farmacobiología, Centro de Investigación y de Estudios Avanzados-Instituto Politécnico Nacional, Mexico City, Mexico.
[Ti] Título:Effect of Serenoa Repens on Oxidative Stress, Inflammatory and Growth Factors in Obese Wistar Rats with Benign Prostatic Hyperplasia.
[So] Source:Phytother Res;29(10):1525-31, 2015 10.
[Is] ISSN:1099-1573
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Serenoa repens has been widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms; however, most of the studies have been conducted in individuals with normal weight and not obese. In this study, the effects of a lipidic extract of S. repens, in markers of oxidative stress, inflammation, and growth factors, in obese rats with testosterone-induced prostatic hyperplasia, were investigated. Total nitrites, malondialdehyde, total glutathione, superoxide dismutase (SOD), and catalase activity were measured; in addition, assays for inflammatory cytokines TNF-α, IL-1ß, IL-6 and the growth factors basic fibroblast growth factor (FGFb) and vascular endothelial growth factor (VEGF) were performed. The obese rats had a higher prostate weight compared with controls. S. repens significantly decreased prostate weight, total nitrites, and malondialdehyde; improved total glutathione, SOD, and catalase activity; and significantly reduced inflammatory (TNF-α, IL-1ß and IL-6) and growth factors (VEGF and FGFb). S. repens showed high antioxidant and antiinflammatory activity in obese rats, suggesting that their use could be beneficial in the treatment of benign prostatic hyperplasia.
[Mh] Termos MeSH primário: Obesidade/tratamento farmacológico
Hiperplasia Prostática/tratamento farmacológico
[Mh] Termos MeSH secundário: Antagonistas de Androgênios/uso terapêutico
Animais
Anti-Inflamatórios/uso terapêutico
Antioxidantes/uso terapêutico
Seres Humanos
Inflamação/tratamento farmacológico
Interleucina-6
Masculino
Obesidade/complicações
Estresse Oxidativo
Fitoterapia
Extratos Vegetais
Hiperplasia Prostática/complicações
Ratos
Ratos Wistar
Serenoa
Fator de Necrose Tumoral alfa
Fator A de Crescimento do Endotélio Vascular
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Interleukin-6); 0 (Plant Extracts); 0 (TNF protein, human); 0 (Tumor Necrosis Factor-alpha); 0 (Vascular Endothelial Growth Factor A); J7WWH9M8QS (saw palmetto extract)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:170301
[Lr] Data última revisão:
170301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150625
[St] Status:MEDLINE
[do] DOI:10.1002/ptr.5406


  10 / 263 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26043832
[Au] Autor:Morabito P; Miroddi M; Giovinazzo S; Spina E; Calapai G
[Ad] Endereço:Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy.
[Ti] Título:Serenoa repens as an Endocrine Disruptor in a 10-Year-Old Young Girl: A New Case Report.
[So] Source:Pharmacology;96(1-2):41-3, 2015.
[Is] ISSN:1423-0313
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Serenoa repens, commonly known as saw palmetto, is the sole species currently classified in the genus Serenoa. The plant is a low shrubby palm that is native of West Indies, and it grows in the coastal lands of North America and other European mediterranean countries. Its fruits contain high concentrations of fatty acids and phytosterols. S. repens extracts have been studied for the symptomatic treatment of benign prostatic hyperplasia. Recently, they have been proposed to treat androgenic alopecia and other hair disorders. We report a new case of hot flashes in a 10-year-old girl using a food supplement containing the extract of S. repens for the treatment of hirsutism. When the girl discontinued the treatment, the hot flashes stopped. A 'rechallenge' of the supplement was tried and symptoms reappeared. About 4 months after starting therapy, the girl experienced menarche. Exposure to the plant-derived product could be responsible for the appearance of menarche. In our opinion, use of phytotherapeutic agents in pediatric patients should be associated to a better evaluation of benefit/risk profile taking in account the physiological changes that occurs at different ages in this subgroup of population.
[Mh] Termos MeSH primário: Disruptores Endócrinos/efeitos adversos
Fogachos/induzido quimicamente
Menarca/efeitos dos fármacos
Extratos Vegetais/efeitos adversos
Serenoa/efeitos adversos
[Mh] Termos MeSH secundário: Criança
Feminino
Frutas
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Endocrine Disruptors); 0 (Plant Extracts)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:150817
[Lr] Data última revisão:
150817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150606
[St] Status:MEDLINE
[do] DOI:10.1159/000431327



página 1 de 27 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde